Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks


Proteomics and Personalized Medicine: Ongoing Partnership

Therapeutic targets are primarily proteins. Their dysregulation and/or mutation led to the initial hypothesis of their causal involvement in specific diseases. In oncology, the majority of these drug targets are identified through genomic nucleic-acid based technologies. As a result, it is more common that the biomarker used to select patients is the genomic aberration. However, protein-based analytical technologies have continued to advance for both research and diagnostic applications.


Scott Patterson, Ph.D., Vice President, Biomarker Sciences, Gilead Sciences

Scott Patterson, PhD, is Vice President, Biomarker Sciences in the R&D organization at Gilead Sciences, Inc, where he is responsible for development and implementation of biomarker and diagnostic strategies across all the company’s therapeutic areas. Read Full Bio

Garry Nolan, Ph.D., Professor in the Department of Microbiology and Immunology, Stanford University

Dr. Nolan is a tenured Professor in the Department of Microbiology and Immunology at Stanford University. He has published over 140 articles (biochemistry, gene cloning and characterization, virology immunology, transcriptional biology, bioinformatics, and signaling). Read Full Bio

Amanda Paulovich, M.D., Ph.D., Clinical Research Division, Fred Hutchinson Cancer Research Center

Amanda Paulovich, M.D., Ph.D. is a Member at Fred Hutchinson Cancer Research Center, and Associate Professor in Medical Oncology at the University Of Washington School Of Medicine. Read Full Bio

Web Analytics